PARIS & WALTHAM, Massachusetts–(BUSINESS WIRE)– Als onderdeel van zijn 20e verjaardag kondigt Echosens, een hoogtechnologisch bedrijf dat de FibroScan®-productfamilie aanbiedt, zijn sponsoring aan van de eerste jaarlijkse Liver Health Matters Month, een bewustmakingsinitiatief in juni om meer bekendheid te geven aan de risico’s van chronische leverziekte, waaronder niet-alcoholische leververvetting (NAFLD), een aandoening waarbij vet zich ophoopt in de lever, de ernstigere vorm niet-alcoholische steatohepatitis (NASH), hepatitis en alcoholgerelateerde leverziekte.

Schattingen tonen aan dat wereldwijd 27 miljoen mensen NASH zullen hebben, een asymptomatische, progressieve en snelgroeiende leverziekte die kan leiden tot verhoogde levergerelateerde mortaliteit en morbiditeit, tegen 2030. FibroScan, een door de FDA goedgekeurd onderzoek voor de diagnose en monitoring van patiënten als onderdeel van een algemene evaluatie van de levergezondheid, meet direct en niet-invasief de fysieke eigenschappen van stijfheid en levervet.

Echosens Sponsors First Annual Liver Health Matters Month in June, Celebrates 20 Years of Battling Liver Disease Epidemic, Preventing Disease Progression

PARIS & WALTHAM, Mass.–(BUSINESS WIRE)– As part of its 20^th anniversary, Echosens, a high-technology company offering the FibroScan^® family of products, is pleased to announce its sponsorship of the first annual Liver Health Matters Month, an awareness initiative in June to heighten recognition about the risks of chronic liver disease, including nonalcoholic fatty liver disease (NAFLD), a condition in which fat builds up in the liver, its more severe form nonalcoholic steatohepatitis (NASH), hepatitis and alcohol-related liver disease.

Estimates show that globally 27 million people will have NASH, an asymptomatic, progressive and burgeoning liver disease that can lead to increased liver-related mortality and morbidity, by 2030. FibroScan, an FDA cleared exam for the diagnosis and monitoring of patients as part of an overall evaluation of liver health, directly and non-invasively measures physical properties of stiffness and liver fat.

Download Echosens’ Liver Health Matters Toolkit here.

“This important awareness campaign will deliver the message to more people about the link between liver disease and obesity, Type 2 diabetes, abnormal levels of fats in the blood and metabolic syndrome,” says Dominique Legros, Group CEO, Echosens. “As sponsors we want to both celebrate the progress we have already achieved with wider use of FibroScan and galvanize the fight to help reverse the progression of liver disease. The need for early identification, assessment and monitoring of liver fat and stiffness has never been more critical.”

He adds that a growing number of self-insured employers and plan sponsors are confronting the alarming statistics about the prevalence of NAFLD and NASH, which is associated with a 3x increase in all-cause mortality in this population, attributable to the addition of liver-related mortality.

Jon Gingrich, CEO, Echosens North America, states, “Liver Health Matters Month will raise public and professional awareness of the critical value of early detection and monitoring of fatty liver disease through traditional and digital media, social networking and community outreach.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan^®, the non-invasive solution for comprehensive management of liver health. FibroScan^® is recognized worldwide and validated by over 2,500 peer reviewed publications and 70 international guidelines. Echosens has made FibroScan^® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005139/en/

Contacts

Brittany Tedesco

CPR Communications

btedesco@cpronline.com
201.641.1911 x 14